UNSPSC 51433607: Pempidine tartrate

This classification denotes a nicotinic antagonist and antihypertensive agent C10H21N.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier THI82M7N4M, chemically known as 1,2,2,6,6-pentamethylpiperidine tartrate, but more generally known as pempidine tartrate, which bears US NIH Compound Identifier 120729. European Medicines Agency schedules Pempidine tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03672MIG.

Most nations, for tariff and trade purposes, schedule pempidine tartrate under HS 29333999 and SITC 51574. As of Q4 2014, PEMPIDINE TARTRATE remains US FDA's Preferred Term for this commodity. SMILES: CC1(CCCC(N1C)(C)C)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.

UNSPSC 51433607 Pempidine tartrate is a Commodity code representing a single pharmaceutical product line procured by state and local health authorities for emergency medical services and pharmacy benefit programs. State and local governments under this code buy advanced life support medications and generic multi-source pharmaceuticals supplied through established wholesaler networks and direct-to-manufacturer channels. The issuing bodies include municipal fire rescue departments, state health and human services commissions, and multistate cooperative purchasing alliances coordinating procurement for participating state agencies and local government facilities. Work solicited ranges from sealed competitive bids for specific medication line items to requests for information on direct pharmaceutical contracting models and cooperative framework agreements establishing pricing and supply relationships for distributed pharmacy networks.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 on April 24, 2026, soliciting four specific advanced life support medication line items—including epinephrine, labetalol, adenosine, and diltiazem—for Tampa Fire Rescue with a response deadline of April 8, 2026 and an estimated contract value of $40,000. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs to support the state's pharmacy benefit objectives. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 on January 20, 2026, due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed through authorized wholesalers to participating state and local facilities in Minnesota and Oregon, with contract effectiveness set for July 1, 2026.